Vanguard S&P 500 Growth Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $87.27 (market cap $27.10B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard S&P 500 Growth Index Fund ETF for 54 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VOOG | ZBH | |
|---|---|---|
Market Cap | $27.10B | $16.95B |
Volume | 1,178,312 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $87.81 | $103.98 |
52-Week Low | $65.32 | $79.58 |
Typical Hold Time | 54 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
VOOG trades at $87.29, down 0.46% on the day, maintaining a bullish technical stance with strong moving average support. The ETF holds 148 large-cap growth stocks from the S&P 500, with significant technology sector exposure. Recent institutional buying activity from firms like Integrated Wealth Concepts and NewEdge Advisors signals confidence in the growth-focused strategy. Technical indicators show bullish momentum with key support at $85 and resistance at $88.
VOOG's long-term growth potential remains compelling with 400% returns over the past decade and 14% gains year-to-date. The ETF's low 0.07% expense ratio and focus on high-performing growth stocks provide cost-effective exposure to market leaders. However, concentration in technology stocks and sensitivity to interest rate changes present risks. The current neutral oscillator readings suggest potential for consolidation near recent highs.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →